Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

212 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L. Haupts M, et al. Among authors: vila c. Eur Neurol. 2016;75(5-6):236-43. doi: 10.1159/000445943. Epub 2016 May 10. Eur Neurol. 2016. PMID: 27160412 Clinical Trial.
Symptoms, prevalence and impact of multiple sclerosis in younger patients: a multinational survey.
Patti F, Vila C. Patti F, et al. Among authors: vila c. Neuroepidemiology. 2014;42(4):211-8. doi: 10.1159/000360423. Epub 2014 May 7. Neuroepidemiology. 2014. PMID: 24821493
Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
Arroyo R, Vila C, Dechant KL. Arroyo R, et al. Among authors: vila c. J Comp Eff Res. 2014 Jul;3(4):435-44. doi: 10.2217/cer.14.30. J Comp Eff Res. 2014. PMID: 25275238 Review.
Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.
Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C. Markovà J, et al. Among authors: vila c. Int J Neurosci. 2019 Feb;129(2):119-128. doi: 10.1080/00207454.2018.1481066. Epub 2018 Sep 13. Int J Neurosci. 2019. PMID: 29792372 Clinical Trial.
The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
Celius EG, Vila C. Celius EG, et al. Among authors: vila c. Brain Behav. 2018 Apr 6;8(5):e00962. doi: 10.1002/brb3.962. eCollection 2018 May. Brain Behav. 2018. PMID: 29761015 Free PMC article. Review.
Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
Trojano M, Vila C. Trojano M, et al. Among authors: vila c. Eur Neurol. 2015;74(3-4):178-85. doi: 10.1159/000441619. Epub 2015 Nov 17. Eur Neurol. 2015. PMID: 26571097
Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
Leocani L, Nuara A, Houdayer E, Schiavetti I, Del Carro U, Amadio S, Straffi L, Rossi P, Martinelli V, Vila C, Sormani MP, Comi G. Leocani L, et al. Among authors: vila c. J Neurol. 2015 Nov;262(11):2520-7. doi: 10.1007/s00415-015-7878-1. Epub 2015 Aug 20. J Neurol. 2015. PMID: 26289497 Clinical Trial.
Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
Meuth SG, Vila C, Dechant KL. Meuth SG, et al. Among authors: vila c. Expert Rev Neurother. 2015;15(8):909-18. doi: 10.1586/14737175.2015.1067607. Epub 2015 Jul 11. Expert Rev Neurother. 2015. PMID: 26166264 Review.
Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.
Slof J, Ruiz L, Vila C. Slof J, et al. Among authors: vila c. Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):379-91. doi: 10.1586/14737167.2015.1025759. Epub 2015 Mar 16. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25771713
Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study.
Arroyo R, Massana M, Vila C. Arroyo R, et al. Among authors: vila c. Int J Neurosci. 2013 Dec;123(12):850-8. doi: 10.3109/00207454.2013.812084. Epub 2013 Jul 15. Int J Neurosci. 2013. PMID: 23819835
212 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page